{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:13:28Z","timestamp":1793654008442,"version":"4.5.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.beha.2019.02.008","type":"journal-article","created":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T11:09:06Z","timestamp":1550315346000},"page":"47-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks"],"prefix":"10.1016","volume":"32","author":[{"given":"Taha","family":"Al-Juhaishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2019.02.008_bib1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib2","unstructured":"Hodgkin Lymphoma - Cancer Stat Facts n.d. https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html (accessed February 3, 2019)."},{"key":"10.1016\/j.beha.2019.02.008_bib3","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood-2007-10-115493","article-title":"Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.008_bib4","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1093\/annonc\/8.suppl_1.S115","article-title":"Hodgkin's disease: complications of therapy and excess mortality","volume":"8","author":"Hoppe","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib5","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1001\/archinte.1970.00310030106013","article-title":"Acute granulocytic leukemia complicating Hodgkin's disease","volume":"125","author":"Steinberg","year":"1970","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beha.2019.02.008_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.1994.12.2.312","article-title":"Second cancer risk following Hodgkin's disease: a 20-year follow-up study","volume":"12","author":"van Leeuwen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2012.44.5791","article-title":"Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials","volume":"31","author":"Koontz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib9","series-title":"NCCN Hodgkin lymphoma clinical practice guidelines in oncology","year":"2018"},{"key":"10.1016\/j.beha.2019.02.008_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM198801143180203","article-title":"Risk of second cancers after treatment for Hodgkin's disease","volume":"318","author":"Tucker","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.02.008_bib11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V59.3.488.bloodjournal593488","article-title":"Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease","volume":"59","author":"Valagussa","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.008_bib12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00043426-199302000-00013","article-title":"High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma","volume":"15","author":"Sugita","year":"1993","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib13","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.02.008_bib14","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 Years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib15","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"123","author":"Eichenauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.008_bib16","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 Years after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.02.008_bib17","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.008_bib18","first-page":"812","article-title":"The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-con","volume":"83","author":"Brusamolino","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2019.02.008_bib19","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3324\/haematol.2017.167478","article-title":"Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials","volume":"102","author":"Eichenauer","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2019.02.008_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnci\/djj017","article-title":"Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35\u2009511 patients","volume":"98","author":"Schonfeld","year":"2006","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.beha.2019.02.008_bib21","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.008_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.02.008_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.02.008_bib24","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib25","first-page":"1891","article-title":"Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma","volume":"43","author":"Greene","year":"1983","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2019.02.008_bib26","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/1097-0142(19821201)50:11<2285::AID-CNCR2820501111>3.0.CO;2-B","article-title":"Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma correlation with intensity of treatment","volume":"50","author":"Gomez","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2019.02.008_bib27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.1996.14.2.565","article-title":"Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma","volume":"14","author":"Travis","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib28","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.2005.04.2200","article-title":"Risk of second malignancy after non-Hodgkin\u2019s lymphoma: a British Cohort study","volume":"24","author":"Mudie","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/1097-0142(19900701)66:1<80::AID-CNCR2820660116>3.0.CO;2-9","article-title":"Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas","volume":"66","author":"Lavey","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2019.02.008_bib30","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-103-2-195","article-title":"Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin\u2019s lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents","volume":"103","author":"Pedersen-Bjergaard","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2019.02.008_bib32","article-title":"Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma","author":"Calip","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2019.02.008_bib33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.12120","article-title":"Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study","volume":"93","author":"Sacchi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2019.02.008_bib34","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.2002.08.128","article-title":"Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011","volume":"20","author":"Morrison","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.008_bib36","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2019.02.008_bib37","first-page":"3580","article-title":"DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2019.02.008_bib38","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1182\/blood-2004-08-3035","article-title":"Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha","volume":"105","author":"McLaughlin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.008_bib39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjh.14667","article-title":"Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma","volume":"178","author":"Martin","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.02.008_bib40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.02.008_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cam4.799","article-title":"Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed\/refractory multiple myeloma patients","volume":"6","author":"Kotchetkov","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.beha.2019.02.008_bib42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clml.2014.07.001","article-title":"Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia","volume":"15","author":"Pemmaraju","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.beha.2019.02.008_bib43","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2019.02.008_bib44","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-120779","article-title":"A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in","volume":"132","author":"Shanafelt","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.008_bib45","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1994.12.12.2527","article-title":"Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies","volume":"12","author":"Darrington","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib46","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.1994.12.12.2535","article-title":"Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma","volume":"12","author":"Stone","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib47","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood.V84.3.957.957","article-title":"Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin\u2019s lymphoma","volume":"84","author":"Traweek","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.008_bib48","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.1994.12.12.2521","article-title":"Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem-cell transplantation","volume":"12","author":"Rohatiner","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib49","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V83.12.3780.3780","article-title":"Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy","volume":"83","author":"Miller","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.008_bib50","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.1999.01627.x","article-title":"Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT lymphoma and late effects working parties. European group for blood and marrow transplantation","volume":"106","author":"Milligan","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2019.02.008_bib51","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/sj.leu.2400809","article-title":"High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure","volume":"11","author":"Pedersen-Bjergaard","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2019.02.008_bib52","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood.V95.11.3273","article-title":"Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation","volume":"95","author":"Pedersen-Bjergaard","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.008_bib53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/10428199609052417","article-title":"Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma","volume":"20","author":"Traweek","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2019.02.008_bib54","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.2006.06.0673","article-title":"Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia","volume":"24","author":"Kalaycio","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib55","first-page":"1814","article-title":"Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation","volume":"94","author":"Abruzzese","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2019.02.008_bib56","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2001.19.9.2472","article-title":"Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma","volume":"19","author":"Lillington","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2019.02.008_bib57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.bmt.1705547","article-title":"Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?","volume":"39","author":"Hake","year":"2007","journal-title":"Bone Marrow Transplant"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261930012X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261930012X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T01:17:40Z","timestamp":1573953460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169261930012X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S152169261930012X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2019.02.008","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2019.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}